Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL).

@article{Kallam2019PhaseIM,
  title={Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL).},
  author={A. Kallam and T. Witzig and M. Roschewski and Elizabeth Lyden and M. Lunning and P. Bierman and G. Bociek and J. Armitage and J. Vose},
  journal={Journal of Clinical Oncology},
  year={2019},
  volume={37}
}
  • A. Kallam, T. Witzig, +6 authors J. Vose
  • Published 2019
  • Medicine
  • Journal of Clinical Oncology
  • e19063Background: Constitutive activation of the JAK-STAT pathway has been reported in lymphomas, suggesting that targeting this pathway could show clinical benefit. Ruxolitinib phosphate, an oral ... 
    1 Citations
    New agents and regimens for diffuse large B cell lymphoma
    • PDF